Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz

Logo MUG-Forschungsportal

Gewählte Publikation:

SHR Neuro Krebs Kardio Lipid Stoffw Microb

Reisinger, AC; Hatzl, S; Prattes, J; Hackl, G; Schilcher, G; Eisner, F; Niedrist, T; Raggam, R; Krause, R; Eller, P.
Soluble urokinase plasminogen activator receptor (suPAR) in bronchoalveolar fluid and blood in critically ill patients-a prospective cohort study.
Infection. 2024; 52(1):249-252 Doi: 10.1007/s15010-023-02127-3 [OPEN ACCESS]
Web of Science PubMed PUBMED Central FullText FullText_MUG

 

Führende Autor*innen der Med Uni Graz
Eller Philipp
Reisinger Alexander Christian
Co-Autor*innen der Med Uni Graz
Eisner Florian
Hackl Gerald
Hatzl Stefan
Krause Robert
Niedrist Tobias Josef
Prattes Jürgen
Raggam Reinhard Bernd
Schilcher Gernot
Altmetrics:

Dimensions Citations:

Plum Analytics:

Scite (citation analytics):

Abstract:
INTRODUCTION: Soluble urokinase plasminogen activator receptor (suPAR) is a biologically active protein and increased levels are associated with worse outcomes in critically ill patients. suPAR in bronchoalveolar fluid (BALF) may be helpful to differentiate between types of acute respiratory distress syndrome (ARDS) and may have potential for early detection of fungal infection. METHODS: We prospectively investigated levels of suPAR in BALF and serum in critically ill patients who underwent bronchoscopy for any reason at the ICU of the Department of Internal Medicine, Medical University of Graz, Graz, Austria. RESULTS: Seventy-five patients were available for analyses. Median age was 60 [25th-75th percentile: 50-69] years, 27% were female, and median SOFA score was 12 [11-14] points. Serum suPAR levels were significantly associated with ICU mortality in univariable logistic regression analysis. There was no correlation between BALF and serum suPAR. Serum suPAR was higher in ARDS patients at 11.2 [8.0-17.2] ng/mL compared to those without ARDS at 7.1 [3.7-10.1] (p < 0.001). BALF-suPAR was significantly higher in patients with evidence of fungal lung infection compared to patients without fungal infection both in the general cohort (7.6 [3.2-9.4] vs 2.5 [1.1-5.3], p = 0.013) and in the subgroup of ARDS (7.2 [3.1-39.2] vs 2.5 [1.0-5.2], p = 0.022). All patients were classified as putative/probable invasive aspergillosis. CONCLUSION: We found significant higher levels of serum suPAR in ARDS patients compared to those not fulfilling ARDS criteria. Serum and BALF-suPAR were significantly higher in those patients with evidence for invasive pulmonary aspergillosis. These findings may suggest testing this biomarker for early diagnosis of fungal infection in a greater cohort.
Find related publications in this database (using NLM MeSH Indexing)
Female - administration & dosage
Humans - administration & dosage
Male - administration & dosage
Middle Aged - administration & dosage
Aspergillosis - administration & dosage
Biomarkers - administration & dosage
Critical Illness - administration & dosage
Prognosis - administration & dosage
Prospective Studies - administration & dosage
Receptors, Urokinase Plasminogen Activator - blood, chemistry
Respiratory Distress Syndrome - diagnosis

Find related publications in this database (Keywords)
suPAR
Critical care
ARDS
Fungi
Aspergillosis
Bronchoalveolar lavage
© Med Uni Graz • Impressum